Solid Tumor Suppliers Serving Alaska

At LAVA, we are focused on applying our expertise in gamma-delta T cell engagers. We are building a pipeline of gamma-delta bsTCEs that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor ...

Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...

Italfarmaco SpA is a private Italian multinational company located in Milan, operating in Italy and abroad in both the pharmaceutical and fine chemical industries through its controlled and/or participated companies. Italfarmaco was establish in ...

Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...

Jubilant Therapeutics Inc. is a clinical stage precision therapeutics company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. With an advanced discovery engine which ...

Sequoia Vaccines is a clinical stage pharmaceutical company discovering and developing new vaccines preventing bacterial infections and medicines treating cancers and bacterial infections. Sequoia’s lead clinical candidate is a vaccine for the ...

MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...

As a leading global provider of diagnostic genomic solutions, our goal is to enable researchers and clinical decision makers to reach the right decisions for each patient, every time. The quality and innovation built into our products for NGS, ...

Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...

SEngine Precision Medicine empowers patients and oncologists with more informed treatment options. SEngine's high-throughput technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The ...

Context is dedicated to developing the next generation of therapies to treat solid tumors, with a primary focus on female cancers. Female cancers include breast, ovarian, and endometrial cancer. To target these cancers, we are advancing bispecific ...

Adaptimmune, a leader in T-cell therapy, has clinical trials ongoing for three wholly owned SPEAR T-cells (ADP-A2M4, ADP-A2M4CD8, and ADP-A2AFP) in multiple solid tumor indications. The Company's unique SPEAR (Specific Peptide Enhanced Affinity ...

Elpiscience is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapies to benefit cancer patients worldwide. Elpiscience has a robust pipeline of globally innovative cancer immunotherapies covering a wide ...

Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing, leveraging our proprietary technology to develop genome-edited off-the-shelf immune cell therapies for the treatment of cancer. We believe that cell ...

With extensive experience optimising processes for analytical, production and R&D laboratories across multiple industries and regulatory environments, we provide consistent, quality informatics solutions. We operate on a truly global basis, serving ...

Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...

We are a biopharmaceutical company dedicated to building novel solutions that treat urothelial and specialty cancers. Our breakthrough therapy and innovative clinical pipeline aim to maximize the potential benefit of local delivery with our novel ...

LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, approaches to develop transformative medicines in neuroscience and immuno-oncology. We are focused on utilizing cutting-edge ...

Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...